Abstract: A dosage inhalator is provided for dispensing to a patient a pharmacologically active compound suspended in a fluid. The dosage inhalator includes a carrier having portions for carrying, by intermittent movement, predetermined and reproducible unit doses of the active compound to a conduit through which it is delivered; a maneuverer for actuating the intermittent movement of the carrier, the maneuverer being movable between first and second predetermined positions by a user of the inhalator; and a member for disrupting the movement of the maneuverer upon exhaustion of the active compound in the storage means. The carrier is actuated by a ratchet mechanism including a spring-biased pawl, the maneuverer includes a lever that is reciprocally displaceable between two distinct positions, and the movement of the ratchet mechanism is limited by the displacement of the lever.

Abstract: Device in a previously known powder inhalator intended for inhalation of an air flow which contains pharmacologically active compound in micronized form. The powder inhalator comprises a nozzle unit (2) with a nozzle aperture (2a) as well as a container unit (3) with a releasing or dosing unit (6) for delivering the active compound. The air flow generated by inhalation is at least partly aspirated through an air conduit (7) located in the container unit (3), which conduit extends from an air inlet (8), communicating with the environment, via said releasing or dosing unit (6), up to said nozzle unit (2). According to the invention, deflector devices are stationarily arranged in the container unit (3) and/or in the nozzle unit (2), said deflector devices, for example in the shape of a helical channel portion (13), being arranged to create a powerful deflecting movement for the purpose of disrupting said powder particles into the respirable particle size distribution (less than 5 .mu.m).

Abstract: A dosage device for dosing with high accuracy a particulate material containing a pharmacologically active substance, including a storage chamber, a rotatable dosing unit adjacent the storage chamber, and an operating unit to cause relative rotation between the dosing unit and the storage chamber. The dosing unit is provided with a plurality of upwardly opening recesses opening into said storage chamber to receive particulate material therefrom through an outlet opening from the storage chamber. Scrapers are positioned in the outlet opening immediately above these recesses to pack and level the particulate material into the recesses and level the material off with the upper surface of the dosing unit as the dosing unit rotates relative to the storage chamber.

Abstract: A dosage inhalator for the inhalation of a pharmacologically active compound in solution form is disclosed. The inhalator comprises a propellant container, a propellant dispensing unit, and a dosing unit for dosing the pharmacologically active compound. The dosing unit comprises a storage chamber for the active compound, a dose loading unit directly connected thereto, and a nozzle. The does loading unit comprises a movable perforated membrane, and a holder for the perforated membrane. The membrane is displaceable between a first position where a solution of active compound is introduced into the perforations of the membrane, and second position where the perforations of the membrane are inserted into a propellant passage.

Abstract: An aerosol inhalation device in pocket-size which has one dosage dispensing position and one storage position, and which comprises a two-part telescoping deceleration chamber (2, 3) with rectangular cross-section and a socket (1) for an exchangeable aerosol container. The socket is connected with the inner chamber part (2) so that it can be telescopically inserted therein to form a storage position. In dosage dispensing position the socket is extended from the deceleration chamber, pivoted at an angle relative to the longitudinal axis of the chamber and locked in the angle.

Abstract: A dosage inhalator for the inhalation of a pharmacologically active compound in solid, micronized form is disclosed. The inhalator comprises a propellant container, a propellant dispensing unit, and a dosing unit for dosing the pharmacologically active compound. The dosing unit comprises a storage chamber for the active compound, a dose loading unit directly connected thereto, and a nozzle. The dose loading unit comprises a movable perforated membrane, and a holder for the perforated membrane. The membrane is displaceable between a first position where active compound is introduced into the perforations of the membrane, and second position where the perforations of the membrane are inserted into a propellant passage. While the membrane is in the second position, the propellant dispensing unit may be operated, allowing propellant originally stored in the propellant container to remove the active compound from the perforations inserted into the propellant passage and carry said compound out the nozzle.

Abstract: A powder inhalator which is activated by the air flow generated at inhalation and which is intended for inhalation of solid pharmacologically active compound in micronized form, said inhalator comprising a nozzle 2, an air conduit 6, a dosing unit 10 comprising a storage chamber 5 for the active compound and dosing means 8, and a maneuvering unit 1, characterized in that the dosing unit 10 comprises a storage chamber 5 for the active compound, a perforated membrane 4, a holder 9 for the said perforated membrane, and dosing means 8 for introducing active compound into the perforations in the perforated membrane 4, whereby means are arranged for displacing the membrane 4 in relation to the dosing means 8, whereby in a first position solid active compound in micronized form is introduced into the perforations in part of the area of the membrane 4 and in a second position the said part of the membrane 4 is inserted in the air conduit 6 for the air to be inhaled.

Abstract: New bronchospasmolytically active compounds exhibiting long duration of action and reduced undesired side effects of the structural formula ##STR1## and therapeutically acceptable salts thereof, in which formula R is selected from the group consisting of --C(CH.sub.3).sub.3, ##STR2## R.sup.1 is selected from the group consisting of H and R.sup.2, R.sup.2 represents the radical of the formula ##STR3## wherein R.sup.3 is selected from the group consisting of(a) H(b) alkyl groups containing 1-3 carbon atoms ##STR4## wherein R.sup.5 is selected from the group consisting of(a) OH(b) alkoxy groups containing 1-3 carbon atoms and whereinR.sup.4 is selected from the group consisting of(a) H(b) alkyl groups containing 1-3 carbon atoms, with the proviso that R.sup.3 and R.sup.4 are combined as follows:______________________________________ when R.sup.3 is then R.sup.

Abstract: New bronchospasmolytically active compounds exhibiting long duration of action and reduced undesired side effects, of the structural formula ##STR1## and therapeutically acceptable salts thereof, in which formula R, R.sup.1 and R.sup.2 are as follows:R is selected from the group consisting of --C(CH.sub.3).sub.3, ##STR2## R.sup.1 is selected from the group consisting of H and R.sup.2 ; R.sup.2 is selected from the group consisting of ##STR3## in which formulas R.sup.3 is selected from the group consisting of (a) H; ##STR4## wherein R.sup.5 is a straight or branched alkyl group containing 1-4 carbon atoms;and ##STR5## and wherein R.sup.4 is selected from the group consisting of(a) H(b) an alkyl group containing 1-3 carbon atoms,process for the preparation thereof, chemical intermediates at their preparation, pharmaceutical compositions containing them and their medicinal use.

Abstract: New bronchospasmolytically active compounds exhibiting long duration of action and reduced undesired side effects of the structural formula ##STR1## and therapeutically acceptable salts thereof, in which formula R is selected from the group consisting of --C(CH.sub.3).sub.3, ##STR2## R.sup.1 is selected from the group consisting of H and R.sup.2, R.sup.2 represents the radical of the formula ##STR3## wherein R.sup.3 is selected from the group consisting of (a) H(b) alkyl groups containing 1-3 carbon atoms ##STR4## wherein R.sup.5 is selected from the group consisting of (e) OH(b) alkoxy groups containing 1-3 carbon atoms and whereinR.sup.4 is selected from the group consisting of(a) H(b) alkyl groups containing 1-3 carbon atoms, with the proviso that R.sup.3 and R.sup.4 are combined as follows:______________________________________ when R.sup.3 is then is R.sup.

Abstract: This invention relates to novel compounds of the general formula ##STR1## Representative compounds within the scope of the invention are ##STR2## The compounds are disclosed as being useful for treating symptoms and signs of cardiac failure by stimulating the .beta.-receptors of the heart. Methods of treatment using these compounds are discussed.

Abstract: An aerosol inhalation device comprising an elongated chamber, an outer chamber part of which has an outlet opening and is telescopically displaceable over an inner chamber part which is connectable to an aerosol dispenser and provided with a flexible tongue which on telescoping the device together closes the outlet opening.

Abstract: This invention relates to novel compounds of the general formula ##STR1## Representative compounds within the scope of the invention are ##STR2## The compounds are disclosed as being useful for treating symptoms and signs of cardiac failure by stimulating the .beta.-receptors of the heart. Methods of treatment using these compounds are discussed.

Abstract: A device for use with a medicinal inhalation device comprises a rotationally symmetrical chamber having an opening to be connected to a spray nozzle and a mouthpiece. The chamber diverges conically from the opening and converges towards the mouthpiece. During passage through the chamber, an aerosol mist will lose propellant by evaporation, and smaller particles will be generated which can more readily follow the path of inhalation.

Abstract: An aerosol inhalation device is designed to use a capsule having a single dose of medication and a propellant. The device includes a hollow needle which perforates the capsule to release the medication. The capsules used with the device include a single dose of medication and an appropriate quantity of propellant.